Differential signaling in response to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) stimulation in the vasculature: modulation of osteopontin expression

被引：0
|
作者：
Berglund, Lisa M. [1 ]
Lyssenko, Valeriya [1 ]
Kotova, Olga [1 ]
Zetterqvist, Anna V. [1 ]
Gottsater, Anders [1 ]
Vaag, Allan [2 ]
Goncalves, Isabel [1 ]
Groop, Leif [1 ]
Gomez, Maria F. [1 ]
机构：
[1] Lund Univ, Malmo, Sweden
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
来源：
FASEB JOURNAL | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] GIP (Glucose-Dependent Inuslinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide 1). Physiological role in the regulation of metabolism and manifestation of type 2 diabetes
    Quast, D.
    Nauck, M. A.
    DIABETOLOGE, 2017, 13 (07): : 475 - 481
  • [42] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [43] Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor (-/-) mice
    Pederson, RA
    Satkunarajah, M
    McIntosh, CHS
    Scrocchi, LA
    Flamez, D
    Schuit, F
    Drucker, DJ
    Wheeler, MB
    DIABETES, 1998, 47 (07) : 1046 - 1052
  • [44] Is carbohydrate and lipid stimulated GLP-1 secretion mediated by glucose-dependent insulinotropic polypeptide (GIP)?
    Hansen, L
    Orskov, C
    Rickelt, L
    Holst, JJ
    DIABETES, 1999, 48 : A200 - A200
  • [45] Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors
    Tura, Andrea
    Bizzotto, Roberto
    Yamada, Yuchiro
    Seino, Yutaka
    Pacini, Giovanni
    Ahren, Bo
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2018, 314 (05) : R639 - R646
  • [46] Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 do not account for the entire incretin effect in healthy humans
    Veedfald, S.
    Sun, Y.
    Xiang, C.
    Xie, C.
    Wu, T.
    Bound, M.
    Grivell, J.
    Hartmann, B.
    Jones, K.
    Horowitz, M.
    Holst, J. J.
    Rayner, C. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S48 - S48
  • [47] Glucose-dependent insulinotropic peptide and glucagon-like peptide-1 in impaired glucose tolerant states: Role of the duodenum
    Theodorakis, M
    Carlson, O
    Michopoulos, S
    Doyle, M
    Juhaszova, M
    Petraki, K
    Egan, J
    DIABETES, 2003, 52 : A77 - A77
  • [48] Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice
    Maida, Adriano
    Hansotia, Tanya
    Longuet, Christine
    Seino, Yutaka
    Drucker, Daniel J.
    GASTROENTEROLOGY, 2009, 137 (06) : 2146 - 2157
  • [49] The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selectivelong-acting GLP-1 receptor agonists
    Urva, Shweta
    Coskun, Tamer
    Loghin, Corina
    Cui, Xuewei
    Beebe, Emily
    O'Farrell, Libbey
    Briere, Daniel A.
    Benson, Charles
    Nauck, Michael A.
    Haupt, Axel
    DIABETES OBESITY & METABOLISM, 2020, 22 (10): : 1886 - 1891
  • [50] Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy
    Malik, Is-Haq O.
    Petersen, Max C.
    Klein, Samuel
    OBESITY, 2022, 30 (09) : 1718 - 1721
12345